Berge Leon Alexander Mclaren, Andreassen Bettina Kulle, Stenehjem Jo Steinson, Heir Trond, Karlstad Øystein, Juzeniene Asta, Ghiasvand Reza, Larsen Inger Kristin, Green Adele C, Veierød Marit Bragelien, Robsahm Trude Eid
Department of Research, Cancer Registry of Norway, Oslo, Norway.
Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Clin Epidemiol. 2020 Dec 18;12:1389-1401. doi: 10.2147/CLEP.S269446. eCollection 2020.
Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level.
In the Cancer Registry of Norway, we identified all cases aged 18-85 with a first primary cutaneous melanoma diagnosed in 2007-2015 (n=12,106). These were matched to population controls from the Norwegian National Registry 1:10 (n=118,564), on sex and year of birth using risk set sampling. Information on prescribed drugs (2004-2015) was obtained by linkage to the Norwegian Prescription Database (NorPD). Conditional logistic regression was used to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for associations between use of immunomodulating drugs (immunosuppressants and corticosteroids) and melanoma risk, adjusted for ambient UVR and other drug use.
Compared with ≤1 prescription, use of ≥8 prescriptions of immunosuppressants was associated with increased risk of melanoma (RR 1.50, 95% CI 1.27, 1.77). Similar associations were found for subgroups of immunosuppressants: drugs typically prescribed to organ transplant recipients (OTRs) (RR 2.02, 95% CI 1.35, 3.03) and methotrexate (RR 1.27, 95% CI 1.04, 1.55). Similar results were found for high levels of cumulative doses and across all histological subtypes. Use of corticosteroids was not associated with melanoma risk.
We found a positive association between use of immunosuppressants and melanoma risk, with the highest risk seen for drugs prescribed to OTRs. Knowledge about this risk increase is important for physicians and users of these drugs, for intensified surveillance, awareness and cautious sun exposure.
皮肤黑色素瘤是挪威增长最快的恶性肿瘤之一,紫外线辐射(UVR)暴露是主要的环境风险因素。免疫调节药物可增加皮肤光敏性并抑制免疫反应,并通过这些机制影响黑色素瘤风险。因此,我们旨在在全国人群水平上研究免疫调节药物的使用与黑色素瘤风险之间的关联。
在挪威癌症登记处,我们确定了所有年龄在18 - 85岁之间、于2007 - 2015年首次诊断为原发性皮肤黑色素瘤的病例(n = 12,106)。使用风险集抽样方法,按照性别和出生年份将这些病例与挪威国家登记处的人群对照进行1:10匹配(n = 118,564)。通过与挪威处方数据库(NorPD)链接获取2004 - 2015年的处方药信息。采用条件逻辑回归来估计免疫调节药物(免疫抑制剂和皮质类固醇)的使用与黑色素瘤风险之间关联的率比(RRs)和95%置信区间(CIs),并对环境UVR和其他药物使用情况进行了调整。
与≤1次处方相比,使用≥8次处方的免疫抑制剂与黑色素瘤风险增加相关(RR 1.50,95% CI 1.27,1.77)。在免疫抑制剂亚组中也发现了类似的关联:通常开给器官移植受者(OTRs)的药物(RR 2.02,95% CI 1.35,3.03)和甲氨蝶呤(RR 1.27,95% CI 1.04,1.55)。在高累积剂量和所有组织学亚型中也发现了类似结果。皮质类固醇的使用与黑色素瘤风险无关。
我们发现免疫抑制剂的使用与黑色素瘤风险之间存在正相关,其中开给OTRs的药物风险最高。了解这种风险增加对这些药物的医生和使用者来说很重要,有助于加强监测、提高认识并谨慎防晒。